Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration.

ABSTRACT: Diabetes, and several diseases related to diabetes, including cancer, cardiovascular diseases and neurological disorders, represent one of the major ongoing threats to human life, becoming a true pandemic of the 21st century. Current treatment strategies for diabetes mainly involve promoting β-cell differentiation, and one of the most widely studied targets for β-cell regeneration is DYRK1A kinase, a member of the DYRK family. DYRK1A has been characterized as a key regulator of cell growth, differentiation, and signal transduction in various organisms, while further roles and substrates are the subjects of extensive investigation. The targets of interest in this review are implicated in the regulation of β-cells through DYRK1A inhibition-through driving their transition from highly ineffic

SUBMITTER: Pucelik B 

PROVIDER: S-EPMC8396662 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature